ATSM CU-64 is an agent for imaging hypoxia in tissues. The agent was developed to be used in PET diagnostic imaging of cancer and showed positive results in phase II of clinical trials in patients with cervical cancer.

Nemadectin (LL-F28249-a) is a macrocyclic lactone antibiotic demonstrating broad-spectrum endectocidal and nematocidal activity. Nemadectin, the dominant member of a class of milbemycins bearing unsaturated longer chain group at the C25 position, is commonly used as a starting material for the commercial anthelmintic moxidectin.

Indolidan is 2-indolinone derivative patented by American pharmaceutical company Eli Lilly and Co as inotropic agents useful for the treatment of heart failure. Indolidan acts as a phosphodiesterase III inhibitor and decreased the thrombin-induced increase endothelial permeability.

Mebolazine is an androgenic anabolic steroid.

Ganglefene is a coronary vasodilator. This n-cholinoblocker was originally studied for its effects on coronary circulation in angina pectoris. Animal studies have also shown shortened recovery period of motor functions after ganglefene administration. One rodent study showed that modulation of the n-cholinergic system by ganglefene in the developing fetal brain leads to changes in the quantitative and qualitative characteristics of elements of sexual behavior in pubescent offspring.

Basimglurant is a potent, selective, and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration, good brain penetration, and high in vivo potency. It has antidepressant properties that are corroborated by its functional magnetic imaging profile as well as anxiolytic-like and antinociceptive features. In electroencephalography recordings, basimglurant shows wake-promoting effects followed by increased delta power during subsequent non-rapid eye movement sleep. Basimglurant has favorable drug-like properties, a differentiated molecular mechanism of action, and antidepressant-like features that suggest the possibility of also addressing important comorbidities of MDD including anxiety and pain as well as daytime sleepiness and apathy or lethargy. Basimglurant is being under development by Roche for the treatment of treatment-resistant depression (as an adjunct). It is in phase II clinical trials for this indication.

Andrographolide, a diterpenoid, is known for its anti-inflammatory effects. It can be isolated from various plants of the genus Andrographis, commonly known as 'creat'. Andrographolide has been tested for its anti-inflammatory effects in various stressful conditions, such as ischemia, pyrogenesis, arthritis, hepatic or neural toxicity, carcinoma, and oxidative stress. Apart from its anti-inflammatory effects, andrographolide also exhibits immunomodulatory effects by effectively enhancing cytotoxic T cells, natural killer (NK) cells, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). The properties of andrographolide, such as its ability to induce apoptosis of cancer cells and inhibition of DTH, its anti-oxidative and cytoprotective effect, and its ability to enhance CTLs and NK cell activation makes it a potent antiviral agent. Andrographolide inhibited the growth of human breast, prostate, and hepatoma tumors. Andrographolide could be a potent anticancer agent when used in combination with other chemotherapeutic agents.

Narlaprevir (formerly SCH 900518), a NS3 protease inhibitor is being developed by R-Pharm for the treatment of a chronic hepatitis C (genotype 1). Narlaprevir is a potent inhibitor of hepatitis C virus (HCV) NS3 protease with a Ki of 7 ± 1 nM and a 90% inhibitory concentration (IC90) of ∼28 ng/ml for HCV genotype 1 replicon in vitro. Narlaprevir successfully passed extensive pre-clinical and clinical trials in Schering-Plough Research Institute (USA) and in a variety of clinical centers of Europe, USA and Russia. Based on clinical findings R-Pharm obtained a registration certificate for Arlansa (Narlaprevir) ЛП-003622 dd 12.05.2016 issued by Ministry of Healthcare of the Russian Federation.

Atagabalin, also known as PD-0200390, was studied in phase II clinical trials in patients with primary insomnia, but this trial was discontinued because of the unsatisfied results. Atagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channels